HOME   Cart(0)   Quotation   About-Us Policy PDFs Standard-List
www.ChineseStandard.net Database: 189760 (18 Oct 2025)

YY/T 1240-2023 English PDF

US$279.00 · In stock
Delivery: <= 3 days. True-PDF full-copy in English will be manually translated and delivered via email.
YY/T 1240-2023: (D-dimer assay kit (immunoturbidimetric method))
Status: Valid

YY/T 1240: Evolution and historical versions

Standard IDContents [version]USDSTEP2[PDF] delivered inStandard Title (Description)StatusPDF
YY/T 1240-2023English279 Add to Cart 3 days [Need to translate] (D-dimer assay kit (immunoturbidimetric method)) Valid YY/T 1240-2023
YY/T 1240-2014English160 Add to Cart 0--9 seconds. Auto-delivery D-Dimer reagent (kit) Obsolete YY/T 1240-2014

PDF similar to YY/T 1240-2023


Standard similar to YY/T 1240-2023

YY/T 1244   YY/T 1235   YY/T 1247   YY/T 1233   YY/T 1230   

Basic data

Standard ID YY/T 1240-2023 (YY/T1240-2023)
Description (Translated English) (D-dimer assay kit (immunoturbidimetric method))
Sector / Industry Medical Device & Pharmaceutical Industry Standard (Recommended)
Classification of Chinese Standard C44
Classification of International Standard 11.100.10
Word Count Estimation 13,183
Date of Issue 2023-01-13
Date of Implementation 2023-07-15
Issuing agency(ies) State Drug Administration
Summary This standard specifies the requirements, test methods, signs, labels and instructions for use, packaging, transportation and storage of D-dimer assay kit (immunoturbidimetric method). This standard applies to kit products for the determination of D-dimer by immunoturbidimetric method.

YY/T 1240-2023: (D-dimer assay kit (immunoturbidimetric method))

---This is a DRAFT version for illustration, not a final translation. Full copy of true-PDF in English version (including equations, symbols, images, flow-chart, tables, and figures etc.) will be manually/carefully translated upon your order.
ICS 11.100.10 CCSC44 Pharmaceutical Industry Standard of the People's Republic of China Replacing YY/T 1240-2014 D-dimer Assay Kit D-dimer testing kit Released on 2023-01-13 2023-07-15 Implementation Released by the State Drug Administration

foreword

This document is in accordance with the provisions of GB/T 1.1-2020 "Guidelines for Standardization Work Part 1.Structure and Drafting Rules for Standardization Documents" drafting. This document replaces YY/T 1240-2014 "D-dimer quantitative detection reagent (box)", compared with YY/T 1240-2014, except for the structure In addition to reconciling editorial changes, the main technical changes are as follows. a) the name of the standard has been changed; b) Added blank limit requirements (see 4.2); c) The test interval is renamed linear, and the deviation is expressed in segments (see 4.3, 4.3 of the.2014 edition); d) In the precision test method, the concentration range of low-value quality control or plasma sample and high-value quality control or plasma sample is clearly defined (see 5.5, 5.5 of the.2014 edition); e) In the repeatability, the requirement that the product is used for the exclusion of venous thromboembolism (VTE) in patients with low pretest probability is added (see 4.4.1,.2014 version of 4.4.1); f) Increased accuracy requirements (see 4.5); g) Simplified the presentation of the reporting method (see 4.7, 4.6 of the.2014 edition); h) YY/T 0466.1 is used instead of GB/T 191 for signs and labels (see 7.1, 7.1 of the.2014 edition); i) The original 4.2 Negative Prediction Rate requirements are deleted and added to the chapter "Signs, Labels and Instructions for Use" (see Chapter 6,.2014 Edition Chapter 6); j) According to the performance characteristics of D-dimer reagents in Appendix B "Applicability of D-dimer reagents", its clinical application can be Will be divided into three categories merged into two categories (see Appendix B, Appendix B of the.2014 edition). Please note that some contents of this document may refer to patents. The issuing agency of this document assumes no responsibility for identifying patents. This document is proposed by the State Drug Administration. This document is under the jurisdiction of the National Medical Clinical Laboratory and In Vitro Diagnostic System Standardization Technical Committee (SAC/TC136). This document was drafted by. The First Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing Institute of Medical Device Testing, Beijing Medical Device Evaluation and Inspection Center, Jilin Provincial Drug Evaluation Center, Shandong Aikeda Biotechnology Co., Ltd., Sysmex Medical Electronics (Shanghai) Co., Ltd. Co., Ltd., Beijing Stargao Diagnostic Products Trading Co., Ltd., Beijing Secside Technology Co., Ltd., Shenzhen Mindray Biomedical electronics co., ltd. The main drafters of this document. Li Mianyang, Xu Yong, Sun Rong, Liu Liu, Di Ping, Li Jian, Li Tan, Guo Xin, Ding Chonghui, Zhao Yumei. The release status of previous versions of this document and the documents it replaces are as follows. ---First released in.2014 as YY/T 1240-2014; --- This is the first revision. D-dimer Assay Kit (Immunoturbidimetry)

1 Scope

This document specifies the requirements, test methods, signs, labels and instructions for use of the D-dimer assay kit (immunoturbidimetric method), package Packing, transportation and storage. This document is applicable to the kit products for the determination of D-dimer by immunoturbidimetric method (hereinafter referred to as D-dimer reagent).

2 Normative references

The contents of the following documents constitute the essential provisions of this document through normative references in the text. Among them, dated references For documents, only the version corresponding to the date is applicable to this document; for undated reference documents, the latest version (including all amendments) is applicable to this document. GB/T 29791.2 Information provided by manufacturers of in vitro diagnostic medical devices (labelling) Part 2.In vitro diagnostic reagents for professional use YY/T 0466.1 Symbols for Medical Device Labeling, Marking and Information Provision for Medical Devices Part 1.General Requirements

3 Terms and Definitions

The following terms and definitions apply to this document. 3.1 Uniform latex particles coated with monoclonal antibody and soluble fibrin degradation products with DD epitopes in plasma The heterosexual combination makes the latex particles stick to each other, and the degree of agglutination is proportional to the concentration of D-dimer in the specimen. At a certain wavelength, the pass The amount of D-dimer is obtained by measuring the change in transmitted or scattered light caused by agglutination.

4 requirements

4.1 Appearance Appearance should meet the following requirements. a) The appearance of the kit should be neat and tidy, and the text and symbols should be clearly marked; b) The D-dimer latex reagent should be a uniform emulsion (this requirement should be met after the dry powder reagent is reconstituted); c) The D-dimer buffer is a clear solution without precipitates or flocs. 4.2 Blank limit The blank limit of the D-dimer reagent should not exceed 0.25 μg/mL. 4.3 Linearity In the linear range, the linear correlation coefficient should be greater than 0.980.The linear range covers at least that provided by the manufacturer for venous thromboembolism